Morepen Proposes Dividend After 23 Years as FY25 Profit Surges
In a significant development, Morepen Laboratories, a leading manufacturer of APIs, branded and generic formulations, and home health products, has proposed a dividend of ₹0.20 per share after a gap of 23 years. The company’s board has approved the proposal, pending shareholder approval at the Annual General Meeting (AGM). This news comes on the back of impressive FY25 results, with the company reporting a surge in profits and revenues.
Morepen Laboratories has been a stalwart in the pharmaceutical industry, with a portfolio of products that cater to the healthcare needs of patients worldwide. The company’s FY25 results are a testament to its strong performance, with gross revenue increasing by 7.4% to ₹1,830 crore. The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose 11.5% to ₹192 crore, while Profit After Tax (PAT) surged to ₹118 crore, resulting in a 17% increase in Earnings Per Share (EPS).
The company’s decision to propose a dividend after 23 years is a significant development, indicating the confidence it has in its financial performance and future prospects. The dividend proposal is a clear indication of the company’s commitment to returning value to its shareholders, who have been waiting for a long time to receive dividends.
Morepen Laboratories has a strong track record of innovation and has been at the forefront of developing new products and formulations. The company’s focus on research and development has enabled it to stay ahead of the competition and expand its product portfolio. The company’s strong R&D capabilities have also enabled it to cater to the changing healthcare needs of patients and respond to emerging trends in the industry.
The company’s FY25 results are a reflection of its strong operational performance, with its manufacturing facilities operating at optimal levels. The company’s focus on quality and compliance has enabled it to meet the stringent regulatory requirements of various countries, including the United States, Europe, and Asia. The company’s strong operational performance has also enabled it to maintain its market share and expand its footprint in international markets.
The dividend proposal is likely to be well-received by investors, who have been waiting for a long time to receive dividends from the company. The dividend yield of ₹0.20 per share is likely to be attractive to investors, given the company’s strong financial performance and future prospects. The dividend proposal is also likely to boost investor confidence in the company, which has been trading at a low valuation compared to its peers.
In conclusion, Morepen Laboratories’ decision to propose a dividend after 23 years is a significant development that is likely to be well-received by investors. The company’s strong FY25 results, with a surge in profits and revenues, indicate its strong operational performance and future prospects. The dividend proposal is a clear indication of the company’s commitment to returning value to its shareholders and is likely to boost investor confidence in the company.
